We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.50
Bid: 46.00
Ask: 47.00
Change: -0.25 (-0.53%)
Spread: 1.00 (2.174%)
Open: 45.75
High: 46.50
Low: 45.50
Prev. Close: 46.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Fri, 01st May 2020 13:28

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Friday and not separately reported by Alliance News:

----------

Avacta Group PLC - biotherapeutics - Partnering with US-based Adeptrix to develop Covid-19 antigen test.

----------

Genedrive PLC - molecular diagnostics - Says development of SARS-CoV-2 testing kit passes manufacturing milestone. On track for CE marking in roughly three weeks.

----------

Inspiration Healthcare Group PLC - medical equipment - Says first consignment of ventilators arrived from supplier to the UK to be used by NHS.

----------

Frontier IP Group PLC - investor - Molendotech investee secures GBP425,000 in equity raise to fund development of rapid testing product for harmful bacteria. Says product receiving interest from potential customers attempting to tackle Covid-19.

----------

Catenae Innovation PLC - digital media - Builds data-protection compliant platform named Cov-ID to track user's Covid-19 test status. Expects project to enter trialling and finalisation phase in mid-May.

----------

Shield Therapeutics PLC - pharmaceuticals - Says manufacturing partners for Feraccru iron deficiency product continuing to work undisrupted. Too early to say whether sales in Germany and UK will hurt by Covid-19.

----------

Metals Exploration PLC - exploration and development - Operations in Philippines reduced to minimum to obey government measures. Says supply chain interruptions have meant some equipment deliveries delayed.

----------

Angus Energy PLC - oil and gas development - Says work to restart gas production at Saltfleetby continuing on schedule. In April sent tenders to bidders for various items for gas production at site. Says delaying bidding deadline due to Covid-19.

----------

Rose Petroleum PLC - oil and gas - Taken action to cost cuts amid virus and failed OPEC talks causing crude market turmoil. Directors taking 50% salary cut. Seeking shareholder approval for name change to Zephyr Energy PLC following restructuring last year.

----------

Rainbow Rare Earths Ltd - rare earth element miner - Says Gakara operations in Burundi continued mostly unhampered by Covid-19. Says 100 tonnes of concentrate reached Dar es Salaam, Tanzania by road due to air travel restrictions. Work continuing for maiden JORC resource.

----------

Igas Energy PLC - hydrocarbon producer - Shutting down some operations in May and June due to low oil price and market volatility. Closure to reduce production by about 600 barrels of oil equivalent per day. Will save roughly GBP500,000 in costs over the two months.

----------

Petra Diamonds Ltd - diamond miner - Says South African operations scaled up to 50% capacity as lockdowns ease. Says 3.8 million carats production guidance remains suspended. Chief executive and finance director take 25% salary cut.

----------

Ferro-Alloy Resources Ltd - vanadium mining - Says full-year results delayed amid UK Financial Conduct Authority moratorium. Production of acid-recoverable concentrates temporarily suspended due to Covid-19; other operations continue but at slower pace.

----------

Thor Mining PLC - tungsten explorer - Reducing costs and taking advantage of Covid-19 financial aid by Australian government.

----------

Lekoil Ltd - oil producer - Defers final USD7.6 million tranche of payment to Optimum Petroleum Development Co to cover costs at OPL 310 License. Payment now split into three tranches, starting with USD1.0 million in July before USD2.0 million in September.

----------

Danakali Ltd - potash producer - Says on-site activities in Eritrea suspended due to Covid-19. Expecting reduced costs in second quarter due to savings.

----------

Prairie Mining Ltd - coal developer - Poland operations limited as a result of pandemic travel restrictions.

----------

Bisichi PLC - miner - Says 2019 results delayed beyond April 30, after UK financial regulator allowed an extra two months.

----------

Salt Lake Potash Ltd - potash producer - Says virus has not had material impact on project schedules; operational changes in place to minimise Covid-19 impact. Directors and executives take 40% pay cut to save costs.

----------

Riverstone Credit Opportunities Income PLC - investor - Fair value of portfolio down 4.1% on March 31 from December 31 due to Covid-19 market turmoil and volatile commodity prices.

----------

Princess Private Equity Holding Ltd - investor - Says March 31 net asset value returns negative 14.1% in March alone and negative 14.8% in first quarter amid Covid-19 impact on markets.

----------

Arden Partners PLC - stockbroker - Says start to six months to April 30 was strong, despite UK political uncertainty amid Brexit and general election. Equity trading operation suffered "material losses" amid market response to virus. Says annual costs to be 25% lower year-on-year and board taking 40% salary cut. Some staff furloughed.

----------

James Cropper PLC - paper and advanced materials - Adjusted pretax profit for year ended March 28 to be in excess of GBP6 million, ahead of market expectations. Reports virus has reduced product demand across all divisions.

----------

Brickability Group PLC - construction materials - To begin re-opening of sites from Friday onwards.

----------

Quadrise Fuels International PLC - heavy fuel oil alternatives maker - Says GBP500,000 of cost savings achieved, meaning it can operate until second quarter of 2021 based on existing funds. Says operations continuing to "very good effect" despite Covid-19 restrictions.

----------

HML Holdings PLC - property services - Says profits for year ended March 31 slightly behind management expectations. Does not anticipate long-term impact from Covid-19, but sees reduction in ancillary revenue streams in the short-term.

----------

SpaceandPeople PLC - retail space selling and marketing - Reports GBP1 million funding application under UK's coronavirus business interruption loan scheme is successful.

----------

Bonhill Group PLC - media firm - Biggest impact from pandemic has been on events business. Says most events moved to second quarter. Furloughs 10% of UK workforce, reduces hours and implementes hiring freeze. Says cost cuts have led to savings of GBP2.5 million.

----------

Frontier Developments PLC - video game developer - Says lockdowns boosting demand and video game sales rising. Expects revenue for year to May 31 at top end of GBP65 million and GBP73 million range.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more
27 Mar 2023 13:44

Avacta to present tumour medicine data at cancer research meeting

(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
13 Mar 2023 10:08

Avacta has 'no relationship' with failed tech-focussed bank

(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.

Read more
17 Jan 2023 17:16

Avacta reports positive progress in chemotherapy trial

(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
8 Nov 2022 13:51

Avacta raises GBP64 million to finance Launch Diagnostics purchase

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.

Read more
18 Oct 2022 12:40

Avacta plans to raise GBP62 million; buys Launch Diagnostics

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.

Read more
18 Oct 2022 11:12

Avacta buying Launch Diagnostics for initial £24m

(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.

Read more
29 Sep 2022 11:56

Avacta losses narrow as it progresses clinical programmes

(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.

Read more
29 Sep 2022 11:30

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.

Read more
5 Sep 2022 11:07

AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
5 Sep 2022 10:10

Avacta shares up as drug approved for soft tissue sarcoma treatment

(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma.

Read more
5 Sep 2022 07:16

Avacta's soft tissue sarcoma treatment gets FDA orphan drug designation

(Sharecast News) - Biotechnology company Avacta Group said on Monday that its soft tissue sarcoma treatment has been granted orphan drug designation by the US Food and Drug Administration.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.